Literature DB >> 19342418

Therapy outcome in peritoneal dialysis patients transferred from haemodialysis.

Tomasz Liberek1, Marcin Renke, Bartosz Skonieczny, Karolina Kotewicz, Jolanta Kowalewska, Michal Chmielewski, Jacek Kot, Monika Lichodziejewska-Niemierko, Boleslaw Rutkowski.   

Abstract

BACKGROUND: Haemodialysis (HD) and peritoneal dialysis (PD) should be regarded as complementary methods of renal replacement therapy. Approximately 10-20% of patients on PD are transferred annually to HD due to technique failure. Much smaller proportion of patients changes modality from HD to PD, predominantly due to vascular access problems, cardiac disease or patient preference. The effects of these transfers on therapy outcome, patient and technique survival have not been studied, with research focusing on outcome measures within the single modality and comparisons between the two methods.
METHODS: We have analysed retrospectively a cohort of 264 patients treated with PD in a single PD centre during 1994-2006. Patient characteristics, therapy measures and outcome of patients were compared between patients for whom PD was the initial method of renal replacement therapy (group 1, n = 197) and those transferred to PD from haemodialysis because of complications (group 2, n = 67). The Kaplan-Meier method and Cox proportional hazards multiple regression analysis were used to assess patient and technique survival.
RESULTS: In patients transferred from HD, significantly less had diabetes (11.9% versus 38.1%, P < 0.0001) and there were also significantly more females (57% versus 42.2%, P < 0.05). Baseline Kt/V was significantly higher in the primary PD therapy group (2.46 +/- 0.57 versus 2.11 +/- 0.48, P < 0.001), due to lower residual renal function in patients transferred from HD. Group 2 had also significantly higher peritonitis rate (0.86 versus 0.62 episode/year, P < 0.05). During the time of observation, 71 patients have died, in 100 patients kidney transplantation was performed, 56 were transferred to HD, renal function recovered in 5 and 32 were still on PD at the end of the study. No significant differences were observed in unadjusted patient survival, but technique survival was significantly lower in group 2 (P < 0.05). In the Cox multiple regression model, diabetes status, age and albumin level significantly influenced survival. Relative risk of death was not increased significantly in patients transferred from HD.
CONCLUSIONS: Our data suggest that outcome of patients transferred from HD is similar to that achieved in patients in whom PD is the first choice therapy. Thus, this option should be strongly considered in patients experiencing complications on HD, mainly vascular access problems, heart failure or intradialytic hypotension.

Entities:  

Mesh:

Year:  2009        PMID: 19342418     DOI: 10.1093/ndt/gfp132

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  A New Method to Increase Ultrafiltration in Peritoneal Dialysis: Steady Concentration Peritoneal Dialysis.

Authors:  Vicente Pérez-Díaz; Alfonso Pérez-Escudero; Sandra Sanz-Ballesteros; Guadalupe Rodríguez-Portela; Susana Valenciano-Martínez; Sofía Palomo-Aparicio; Esther Hernández-García; Luisa Sánchez-García; Raquel Gordillo-Martín; Hortensia Marcos-Sánchez
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

2.  Comparison and causes of transfer from one dialysis modality to another.

Authors:  Aydin Unal; Ismail Kocyigit; Murat Hayri Sipahioglu; Bulent Tokgoz; Oktay Oymak; Cengiz Utas
Journal:  Int Urol Nephrol       Date:  2010-09-10       Impact factor: 2.370

3.  Patient outcome in primary peritoneal dialysis patients versus those transferred from hemodialysis and transplantation.

Authors:  Iraj Najafi; Mostafa Hosseini; Shahnaz Atabac; Hushang Sanadgol; Nader Nouri Majelan; Shiva Seirafian; Massih Naghibi; Khadigeh Makhdoumi; Fereshteh Saddadi; Tayebeh Soleymanian
Journal:  Int Urol Nephrol       Date:  2011-11-17       Impact factor: 2.370

4.  The impact of transfer from hemodialysis on peritoneal dialysis technique survival.

Authors:  Sharon J Nessim; Joanne M Bargman; S Vanita Jassal; Matthew J Oliver; Yingbo Na; Jeffrey Perl
Journal:  Perit Dial Int       Date:  2013-12-01       Impact factor: 1.756

5.  Clinical outcomes of peritoneal dialysis patients transferred from hemodialysis: a matched case-control study.

Authors:  Li Zhang; Tao Cao; Zhibin Li; Qiong Wen; Jianxiong Lin; Xiaodan Zhang; Qunying Guo; Xiao Yang; Xueqing Yu; Haiping Mao
Journal:  Perit Dial Int       Date:  2012-11-01       Impact factor: 1.756

6.  Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis.

Authors:  Lilia R Lukowsky; Rajnish Mehrotra; Leeka Kheifets; Onyebuchi A Arah; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-10       Impact factor: 8.237

7.  Would increasing centre volumes improve patient outcomes in peritoneal dialysis? A registry-based cohort and Monte Carlo simulation study.

Authors:  David Evans; Thierry Lobbedez; Christian Verger; Antoine Flahault
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

8.  Educating end-stage renal disease patients on dialysis modality selection.

Authors:  Adrian Covic; Bert Bammens; Thierry Lobbedez; Liviu Segall; Olof Heimbürger; Wim van Biesen; Denis Fouque; Raymond Vanholder
Journal:  NDT Plus       Date:  2010-04-16

9.  Relationship between trajectories of serum albumin levels and technique failure according to diabetic status in peritoneal dialysis patients: A joint modeling approach.

Authors:  Mehri Khoshhali; Iraj Kazemi; S Mohsen Hosseini; Shiva Seirafian
Journal:  Kidney Res Clin Pract       Date:  2017-06-30

10.  Modelling competing risks in nephrology research: an example in peritoneal dialysis.

Authors:  Laetitia Teixeira; Anabela Rodrigues; Maria J Carvalho; António Cabrita; Denisa Mendonça
Journal:  BMC Nephrol       Date:  2013-05-24       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.